Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCash Due from BankCommon EquityDividends payablesFed Funds SoldGoodwillGoodwill & IntangiblesIntangiblesInterest DepositsLiabilities and Shareholders EquityLoansLoans - GrossLoans - Loss AllowanceLoans - NetLong-Term Deferred TaxNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Retained EarningsSecurities - Mortgage Backed SecuritiesSecurities - TradableShareholder's EquityShort-term InvestmentsTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ames National (ATLO) Cash & Equivalents (2017 - 2025)

Historic Cash & Equivalents for Ames National (ATLO) over the last 9 years, with Q3 2025 value amounting to $108.2 million.

  • Ames National's Cash & Equivalents rose 8342.01% to $108.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $108.2 million, marking a year-over-year increase of 8342.01%. This contributed to the annual value of $101.2 million for FY2024, which is 8371.17% up from last year.
  • Latest data reveals that Ames National reported Cash & Equivalents of $108.2 million as of Q3 2025, which was up 8342.01% from $95.2 million recorded in Q2 2025.
  • Ames National's Cash & Equivalents' 5-year high stood at $163.4 million during Q1 2025, with a 5-year trough of $2.0 million in Q4 2021.
  • For the 5-year period, Ames National's Cash & Equivalents averaged around $69.1 million, with its median value being $74.7 million (2022).
  • In the last 5 years, Ames National's Cash & Equivalents surged by 152537.8% in 2022 and then tumbled by 4122.24% in 2023.
  • Ames National's Cash & Equivalents (Quarter) stood at $2.0 million in 2021, then surged by 81.35% to $3.6 million in 2022, then surged by 1427.61% to $55.1 million in 2023, then soared by 83.71% to $101.2 million in 2024, then grew by 6.85% to $108.2 million in 2025.
  • Its Cash & Equivalents stands at $108.2 million for Q3 2025, versus $95.2 million for Q2 2025 and $163.4 million for Q1 2025.